NOVAMSC

Novamsc has been in collection for so long and has embarked first journey since 12.5c. a wavering movement signify that collection has been made at few prices for next journey. A little bit on Nova. The company engaged in software research and development and provision of e-solutions through application software and customization. 

With the AI and Datacentre mania, it is imminent Novamsc is ready to begin what they have prepared for. To recap, in January 2023 Novamsc has termed an MOU with Theta Edge Berhad to collaborate on Healthcare and public sector and applied Artificial Intelligence (A.I). This collaboration had materialised a join venture later in September 2023 with term of equity holding Theta 60% and NOVA 40%. This strategic partnering will benefit both parties in term of:

1. Providing e-government solution

2. IT solutions

3. Ready to deploy software

Aims to address key challenges faced by government agencies and businesses alike, paving the way for a seamless transition to a modern and technologically advanced ecosystem. The primary focus will be on providing Al based services such as "Building Information Modeling" which automate the building plan and design validation which is used by local councils to validate building plans submitted to these councils.

On August 2018, Novamsc completed acquisition of 42% equity interest in Eyris Pte Ltd which principally involved in managing research and experimental development on medical technologies. This in line with Nova’s strategy to introduce AI in industry. 

On May 2020, the group incorporated a new company called DEX- Lab Pte Ltd (DEX-LAB) in Singapore to focus on development and marketing of AI product and services.

Major shareholder is non other than semiconductor tycoon, Mr Ooi Keng Thye (Frontkn Chairman) which hold 16.14% stake. Among others prominent Raden Corporation Sdn Bhd a member of the Negeri Sembilan royal family. Recent acquisition seen is Societe General Paris, the third largest bank of Paris.

Prospect of Novamsc group

NovaMSC has embraced a transformative growth strategy, focusing on four key pillars:

Healthcare, E-Government, Artificial Intelligence, and Robotics.

 NovaMSC's software products:

1. Pavo, an e-Government software designed to streamline the online submission of application documents.

2. Fornax, a software system dedicated to electronic plan check procedures, automating the verification and approval processes for building plans.

3. Avicenna, a fully integrated cloud-based system that comprehensively addresses administrative requirements.

4. Vesalius, a web-based platform that supports the administrative and clinical function within a hospital

5. Dex-lab Pte Ltd, has achieved a significant milestone by creating DEXIE a highly advanced human-looking social robot tailored for the eldercare sector in Singapore. 

6. EyScan, an intelligent deep learning system that performs automated retinal photo analysis, which was developed under EyRIS Pte Ltd ("EyRIS") has made remarkable progress with its Al-driven SELENA+ system, designed for the early detection of eye diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration

EyRIS is set to embark on a groundbreaking study in collaboration with Optometrist Warehouse a division of the Chemist Warehouse Group in Australia. This study will focus on evaluating the effectiveness of Artificial Intelligence ("Al") in screening diabetic retinopathy in the Australian context. As EyRIS continues to make strides in leveraging Al for healthcare, this partnership signifies a significant step forward in addressing critical eye health concerns through cutting-edge technology.

Through the above-mentioned activities, the Group has been intensifying their efforts to drive sales and expand their market presence. 

Rumours been going around that another significant figure will emerge as stakeholder. With the emerging shareholder soon many other hundred million value contracts will flow in to Novamsc

Regards, 

Lily of the valley